Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZII
|
|||
| Former ID |
DAP000374
|
|||
| Drug Name |
Chlorpromazine
|
|||
| Synonyms |
Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1], [2] | |
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H19ClN2S
|
|||
| Canonical SMILES |
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
|
|||
| InChI |
1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
|
|||
| InChIKey |
ZPEIMTDSQAKGNT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 34468-21-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9123, 441206, 602724, 841999, 4332427, 7847336, 7978926, 8149253, 8151764, 10524433, 10588932, 11110990, 11110991, 11120337, 11120825, 11121313, 11335799, 11361038, 11363036, 11364725, 11365598, 11367287, 11368160, 11369849, 11371331, 11372890, 11373945, 11375449, 11376322, 11378013, 11462010, 11466092, 11467212, 11484847, 11485904, 11488972, 11490162, 11492098, 11493956, 12014508, 14923746, 24398080, 25688547, 26611657, 26680205, 26747094, 26747095, 26751620, 26751621, 29221882
|
|||
| ChEBI ID |
CHEBI:3647
|
|||
| ADReCS Drug ID | BADD_D00445 ; BADD_D00446 | |||
| SuperDrug ATC ID |
N05AA01
|
|||
| SuperDrug CAS ID |
cas=000050533
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Chlorpromazine hydrochloride (adjusted p-values: 3.16E-03). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Chlorpromazine hydrochloride (adjusted p-values: 3.26E-05). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Chlorpromazine hydrochloride (adjusted p-values: 3.43E-03). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Chlorpromazine hydrochloride (adjusted p-values: 3.61E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Chlorpromazine hydrochloride (adjusted p-values: 9.27E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Chlorpromazine hydrochloride (adjusted p-values: 3.24E-04). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 83). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080439. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. | |||
| REF 5 | Basolateral amygdala D1- and D2-dopaminergic system promotes the formation of long-term potentiation in the dentate gyrus of anesthetized rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):552-6. | |||
| REF 6 | Behavioral and neurochemical methods in research on new psychotropics. Ann Pharm Fr. 1998;56(2):54-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.